

Supplementary File

Table S1. Adjuvant treatment

Type of adjuvant treatment by criteria				
	Sedlis	Peters	Others*	All
Teletherapy and brachytherapy	30 (28.30)	1 (0.94)	9 (8.49)	40 (37.73)
Chemotherapy and teletherapy	0 (0.0)	1 (0.94)	0 (0.0)	1 (0.94)
Chemotherapy, teletherapy and brachytherapy	16 (15.09)	35 (33.02)	10 (9.43)	61 (57.54)
Missing	2 (1.89)	2 (1.89)	0 (0.0)	4 (3.77)
All	48 (45.28)	39 (36.79)	19 (17.92)	106 (100)
Adjuvant radiotherapy dose [cGy]			7393.06 (±694.61)	
Teletherapy dose [cGy]			4594.40 (±223.90)	
Type of teletherapy n(%)				
3DCRT			14(13.21)	
IMRT			21(19.81)	
2D			66(62.26)	
Missing			5(4.72)	
Brachytherapy dose [cGy]			2146.15(±479.71)	
Type of brachytherapy (n = 101)				
HDR			88(87.13)	
LDR			11(10.89)	
Missing			2 (1.98)	
Chemotherapy agent (n = 62)				
Cisplatin			53 (85.48)	
Carboplatin			1 (1.61)	
Missing			8 (12.90)	

*Others: stromal invasion only (8); low node count (2); narrow margin (2); cervical stromal invasion (1); lymphovascular invasion only (1); clear cells (1); glassy cell (1); mucinous adenocarcinoma (1); concurrent endometrial adenocarcinoma (1); Lymphoepithelioma-like carcinoma (1)

EQD2 — equivalent total doses in 2-Gy fractions; 3DCRT — three-dimensional conformal radiation therapy; IMRT — intensity-modulated radiation therapy; 2D — two dimensional radiation therapy; HDR — high-dose rate; LDR — low dose rate

Table S2. Univariate analysis of risk factors for morbidity

Factor	RR (95% CI)
Intraoperative complications	
No	1
Yes	4.12 (2.97, 5.70)
Adjuvant treatment	
No	1
Yes	1.38 (0.90, 2.13)
Clinical tumor size	
< 2 cm	1
≥ 2 cm	0.78 (0.42, 1.48)
FIGO stage	
IA1 to IA2	1
IB1	1.02 (0.43, 2.46)
Histological type	
Adenocarcinoma or adenosquamous	1
Squamous	0.98 (0.63, 1.53)